Olema Pharmaceuticals, Inc.
OLMAOlema Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing next-generation targeted therapies for endocrine-driven cancers.
Earnings
Next report
Aug 10, 2026 (In 4 weeks)Financials
Q1 2026Valuation & ratios
Competitors
Profile
Olema Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing next-generation targeted therapies for endocrine-driven cancers. The company leverages its expertise in nuclear receptors and mechanisms of acquired resistance to create treatments for patients with recurrent or metastatic breast cancer. Its primary value proposition lies in developing oral small molecules that function as complete estrogen receptor antagonists and selective degraders.
Olema is a clinical-stage developer of potential best-in-class oral endocrine therapies, currently advancing its lead candidate through pivotal Phase 3 trials for metastatic breast cancer.
Questions, answered.
- What is Olema Pharmaceuticals, Inc.'s market cap?
- Olema Pharmaceuticals, Inc. (OLMA) has a market capitalization of $1.1B and trades on NASDAQ.
- Who are Olema Pharmaceuticals, Inc.'s competitors?
- Olema Pharmaceuticals, Inc.'s key competitors include AstraZeneca, Eli Lilly and Company, Sanofi, and others. These companies compete in similar markets and product categories.
- Who does Olema Pharmaceuticals, Inc. partner with?
- Olema Pharmaceuticals, Inc.'s notable partners include Novartis Pharma AG, Pfizer Inc..
- Where is Olema Pharmaceuticals, Inc. headquartered?
- Olema Pharmaceuticals, Inc. is headquartered in United States of America and employs approximately 76 people. It has been publicly traded since 2020.